ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM study reported at the 2013 Genitourinary Cancers…

ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium by Dr Andrew Loblaw from the Sunnybrook Health Sciences Centre …

ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months — but have fewer side effects — according to study findings announced at the 2013 ASCO …

– DENGUE FEVER: Vaccine gives some protection against three out of four virus serotypes.

Other headlines

– HTA: Renal denervation lowers blood pressure independently of drugs

– Eat, drink and be merry: tomorrow you won’t die if you take exercise.

LOS ANGELES—Half of young adults who had multiple, elevated, blood pressure results on recent outpatient visits to the doctor, went home without a hypertension diagnosis. Research presented at the 2012 American Heart Association meeting showed, after four years of trips …

LOS ANGELES—Regardless of climate, there are more deaths from heart-related issues in winter-time than in the summer. Results from a 12-year US population based study with over 220,000 people were presented at the American Heart Association meeting in Los Angeles …

LOS ANGELES—Looking older than your chronological age is a risk factor for cardiovascular disease — at least among white Caucasians — according to a study of over ten thousand Danish people from the general population who were…

SAN ANTONIO, TEXAS—The UK TACT2 trial, looking at over 4 000 patients with early breast cancer, has confirmed that modern chemotherapy is very effective, and continues to contribute to very high cure rates. Professor David Cameron of Edinburgh University explains …

ATLANTA, GEORGIA—A “third generation” tyrosine kinase inhibitor — ponatinib — has succeeded in controlling chronic myeloid leukaemia and Philadelphia-positive acute lymphoblastic leukaemia in patients who have the feared T 315 I mutation — which has prevented…